Insider Holder Move: Corcept Therapeutics Incorporated (NASDAQ:CORT)’s Stock Insider Trade – Patrick Enright Unloaded 36,941 Shares

November 26, 2016 - By Michael Collier

Insider Holder Move: Corcept Therapeutics Incorporated (NASDAQ:CORT)'s Stock Insider Trade   Patrick Enright Unloaded 36,941 Shares

Patrick Enright Insider Sell

Patrick Enright, the director of Corcept Therapeutics Inc made a surprising insider trade for 36,941 shares with an average price per share of $9.3 in the corporation, that are having a total value $345,165 USD. In the last 30 days, he also sold 718,947 shares with a total value of about $6,869,032 USD. This big transaction will probably draw attention, as he presently has rights to 12.71% of the total market cap of the company.

Insitutional Activity: The institutional sentiment increased to 2.23 in Q2 2016. Its up 0.43, from 1.8 in 2016Q1. The ratio increased, as 13 funds sold all Corcept Therapeutics Incorporated shares owned while 22 reduced positions. 24 funds bought stakes while 39 increased positions. They now own 45.31 million shares or 34.44% more from 33.70 million shares in 2016Q1.

Globeflex Capital Ltd Partnership last reported 244,483 shares in the company. Oxford Asset has 97,291 shares for 0.02% of their US portfolio. Ellington Management Gp Limited Co last reported 21,700 shares in the company. Susquehanna Int Group Limited Liability Partnership reported 54,348 shares or 0% of all its holdings. Bnp Paribas Arbitrage Sa holds 0% or 2,903 shares in its portfolio. Campbell & Invest Adviser Lc accumulated 0.43% or 15,794 shares. Envestnet Asset holds 0% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 3,294 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT). Deutsche National Bank Ag holds 0% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 11,417 shares. Schwab Charles Invest Mngmt holds 0% or 116,906 shares in its portfolio. Gotham Asset Llc last reported 0% of its portfolio in the stock. Grp One Trading Lp accumulated 7,699 shares or 0% of the stock. Principal Fincl Grp accumulated 14,878 shares or 0% of the stock. Vanguard Grp Inc Inc accumulated 2.98M shares or 0% of the stock. American Int Grp Incorporated has 43,003 shares for 0% of their US portfolio.

Insider Transactions: Since November 7, 2016, the stock had 0 insider buys, and 8 selling transactions for $24.01 million net activity. The insider BELANOFF JOSEPH K sold 500,000 shares worth $4.49M. $1.67M worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) was sold by ENRIGHT PATRICK G on Tuesday, November 15. $5.20 million worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) shares were sold by Longitude Venture Partners L.P. 158,812 shares were sold by WILSON JAMES N, worth $1.35M. Shares for $280,500 were sold by MAHONEY DAVID L on Friday, November 11.

The stock decreased 1.18% or $0.11 during the last trading session, hitting $9.18. About 357,529 shares traded hands. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 79.30% since April 25, 2016 and is uptrending. It has outperformed by 73.28% the S&P500.

Corcept Therapeutics Inc. is a pharmaceutical firm engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company has a market cap of $1.05 billion. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. It has a 233.71 P/E ratio. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders.

According to Zacks Investment Research, “Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol. It is developing its lead product, CORLUX for the treatment of the psychotic features of psychotic major depression. Corcept Therapeutics Incorporated is headquartered in Menlo Park, California.”

Analysts await Corcept Therapeutics Incorporated (NASDAQ:CORT) to report earnings on March, 7. They expect $0.03 EPS, up 50.00% or $0.01 from last year’s $0.02 per share. CORT’s profit will be $3.43M for 76.50 P/E if the $0.03 EPS becomes a reality. After $0.02 actual EPS reported by Corcept Therapeutics Incorporated for the previous quarter, Wall Street now forecasts 50.00% EPS growth.

More news for Corcept Therapeutics Incorporated (NASDAQ:CORT) were recently published by: Fool.com, which released: “Corcept Therapeutics Rose 18% in March. Here’s Why.” on April 06, 2016. Fool.com‘s article titled: “Why Corcept Therapeutics Incorporated Shares Were Mauled” and published on May 07, 2014 is yet another important article.

CORT Company Profile

Corcept Therapeutics Inc., incorporated on May 13, 1998, is a pharmaceutical firm engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders. The Firm is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). The Firm also has discovered approximately three structurally distinct series of selective cortisol modulators, all of which share mifepristone’s affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor, and so do not terminate pregnancy or cause other side effects associated with progesterone receptor antagonism. The Firm has begun pre-clinical and clinical development of its lead compounds from these series.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>